Did Everolimus Break the Rules?

Shumei Kato; Ezra E W Cohen

doi:10.1158/1078-0432.CCR-21-1508

Did Everolimus Break the Rules?

Clin Cancer Res. 2021 Jul 15;27(14):3807-3808. doi: 10.1158/1078-0432.CCR-21-1508. Epub 2021 May 13.

Authors

Shumei Kato¹, Ezra E W Cohen²

Affiliations

¹ Division of Hematology-Oncology, Department of Internal Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, California.
² Division of Hematology-Oncology, Department of Internal Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, California. ecohen@health.ucsd.edu.

PMID: 33986025
DOI: 10.1158/1078-0432.CCR-21-1508

Abstract

A phase II study with everolimus (mTORC1 inhibitor) among advanced solid tumors patients with TSC1/TSC2 or MTOR alterations was recently published. Although efficacy was limited, the study provided the future groundwork to advance the targeted therapy approach.See related article by Adib et al., p. 3845.

Publication types

Comment

MeSH terms

Everolimus*
Humans
Mechanistic Target of Rapamycin Complex 1
Tuberous Sclerosis Complex 2 Protein

Substances

Tuberous Sclerosis Complex 2 Protein
Everolimus
Mechanistic Target of Rapamycin Complex 1